A bispecific antibody is an antibody that includes two different antigen binding sites of monoclonal antibodies that can bind to two different antigens. There are more than 100 different designs of bispecific antibodies as described by Brinkmann et al, 2017.
Since the bispecific antibody can bind two different antigens, it can bind T cells and cancer associated antigen such as CD19-CD3 (Amgen); CEA-CD3, EpCAM-CD3 and others. Bispecific antibodies can recruit T cells by binding CD3 to cancer cells, leading to the secretion of cytokines, granzyme, perforin and ultimately leading to the killing of cancer cells (Figure 1).
Starting at $26,000
The structural type of the bispecific antibody can vary immensely. We can design any type of antibody using our gene-engineering platform and can express these antibodies in mammalian cells (such as HEK293, CHO cells) for large scale production.
Generating a bispecific antibody will need extensive experimentation for the project’s needs. ProMab’s custom bispecific antibody service includes several steps.
|Phase I *||Generate up to 3 sequences with different designs
Generate recombinant antibody DNA plasmid de novo
|Phase II||Generation of bi-specific antibody proteins.
Small-scale expression into mammalian cell lines.
Verification by SDS-page.
Binding analysis by ELISA with recombinant protein antigen.
Clones are compared to parental antibody.
|Phase III||Regeneration of top 2 full length bispecific antibodies.
Binding analysis by ELISA.
ELISA evaluation of antibodies recognized by anti-mouse antibodies.
|Phase IV||Large scale antibody production||Inquire|
Additional Add-On Services
|FACS Analysis||Binding analysis by FACS with antigen positive cell lines.||$500|
|Octet BLI Binding Assay||Antibody binding affinity analysis by Octet system bio-layer interferometry||$1000|
|BiacoreTM SPR Biosensors||Binding and kinetics analysis using BiacoreTM SPR biosensors to determine antibody affinity, Ka, Kd, KD values||$3200|
Being an antibody development company that has ventured and prevailed into the CAR-T development space, ProMab holds several advantages over our competitors.
One unique advantage ProMab offers is that we have developed many different stable cell lines with tumor antigens to validate many bispecific antibodies. For example: Hela-CD19 cells, CHO-CD22, CHO-CS1, CHO-BCMA, CHO-CD37 , and others.
ProMab has also invested in cutting-edge technology with in-vitro assays utilizing XCelligenceTM System (ACEA/Agilent), as well as an in-house animal facility for in-vivo validation.